Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2023 MDS Highlights
01 February 2024 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in myelodysplastic syndromes (MDS) from ASH 2023
The Post-ASH 2023 MDS Highlights was supported by Bristol Myers Squibb, Genentech and Geron. Supporters have no influence over the production of content.
Session 1: Non-disease modifying agents in LR-MDS
COMMANDS: Luspatercept vs EPO alfa in ESA-naive pts with TD LR-MDS
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States
MEDALIST: Luspatercept in ESA-intolerant/refractory pts with LR-MDS
Valeria Santini University of Florence, Florence, Italy
MATTERHORN: roxadustat for treating anemia in pts with LR-MDS
Moshe Mittelman Tel Aviv University, Tel Aviv, Israel
Durable clinical benefit with KER-050
María Díez Campelo University of Salamanca, Salamanca, Spain
Panel discussion: non-disease modifying agents in LR-MDS
Session 2: Disease-modifying agents
IMerge: efficacy of imetelstat in achieving RBC transfusion independence
Uwe Platzbecker University Hospital Carl Gustav Carus, Dresden, Germany
Olutasidenib +/- azacitidine in mIDH1 MDS
Jorge Cortes Georgia Cancer Center, Augusta University, Augusta, GA, United States
STIMULUS-MDS1: MRD clearance is associated with improved clinical outcomes
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Guadecitabine in HR-MDS & CMML
Samuel Urrutia Washington University School of Medicine, St. Louis, MO, United States
Panel discussion: disease-modifying agents
Session 3: Venetoclax-based regimens
Venetoclax with azacitidine for treatment-naive HR-MDS
Jacqueline Garcia Dana-Farber Cancer Institute, Boston, MA, United States
Venetoclax improves response rates but not survival in CMML
Douglas Tremblay Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Oral decitabine/cedazuridine with venetoclax in HR-MDS or CMML
Alex Bataller MD Anderson Cancer Center, Houston, TX, United States
Panel discussion: venetoclax-based regimens
Session 4: Classification, prognostication and treatment patterns
Molecular taxonomy of MDS and its clinical implications
Elsa Bernard Memorial Sloan Kettering Cancer Center, New York, NY, United States
Data-driven harmonization of 2022 WHO and ICC classifications of MDS
Matteo Della Porta Humanitas Research Hospital, Milan, Italy
Reclassification of ascertain (ASTX727-02) MDS
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States
The Composite Complete Response definitions in the IWG 2023 criteria
Jan Bewersdorf Yale Cancer Center, New Haven, CT, United States
Real-world treatment patterns among pts with MDS
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Panel discussion: classification, prognostication and treatment patterns
The Post-ASH 2023 MDS Highlights has been supported by:
